Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to 0.44%.

  • Lineage Cell Therapeutics' Return on Capital Employed fell 1700.0% to 0.44% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.44%, marking a year-over-year decrease of 1700.0%. This contributed to the annual value of 0.23% for FY2024, which is 300.0% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Return on Capital Employed stood at 0.44% for Q3 2025, which was down 1700.0% from 0.39% recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Return on Capital Employed registered a high of 0.21% during Q4 2022, and its lowest value of 0.47% during Q4 2021.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.27% (2023), whereas its average is 0.3%.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Return on Capital Employed tumbled by -1900bps in 2021 and then skyrocketed by 2600bps in 2022.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Return on Capital Employed stood at 0.47% in 2021, then soared by 55bps to 0.21% in 2022, then tumbled by -39bps to 0.29% in 2023, then rose by 18bps to 0.24% in 2024, then tumbled by -84bps to 0.44% in 2025.
  • Its Return on Capital Employed was 0.44% in Q3 2025, compared to 0.39% in Q2 2025 and 0.21% in Q1 2025.